During the past decade, a variety of innovative procedures and devices for non-pharmacological treatment of tachyarrhythmias have been proposed. Recent improvements in the implantable cardioverter/defibrillators and transcatheter ablative techniques have resulted in a revolution of the therapeutic approach in ventricular and supraventricular tachyarrhythmias, respectively, providing a valuable alternative to conventional antiarrhythmic surgery. Indeed, the selection criteria for surgery for tachyarrhythmias have been revised, and this therapeutic option is considered appropriate only for selected patients with postinfarction ventricular tachycardia. Ther implantable cardioverter/defibrillator has proved effective in conversion of life-threatening tachyarrhythmias, leading a dramatic decrease in the incidence of sudden death in high risk subjects. Thus, with further refinements, a wide use of this therapeutic modality can be anticipated. Transcatheter ablation has become the first-line option in the most common forms of supraventricular tachycardias, such as accessory pathway-mediated tachycardia and AV nodal reentry. More recently, encouraging results of this technique in common atrial flutter and ectopic atrial tachycardia have been reported, although confirmation with larger series and longer follow-up is needed. In general, results of catheter ablation in ventricular tachycardia have been disappointing, with the exception of bundle branch reentry and idiopathic ventricular tachycardia, in which a high success rate is reported. An increasingly important role of these therapeutic modalities is expected. In the meanwhile, due to their evolutional character and the specific competence required for their use, such procedures should be performed exclusively in well trained centers.